Spinal Cord Injury Pipeline Insight Report 2021: Approx 35 Companies & 35 Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--()--The "Spinal Cord Injury - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Spinal cord injury - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Spinal cord injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Spinal cord injury Emerging Drugs Chapters

This segment of the Spinal cord injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spinal cord injury Emerging Drugs

KP-100IT: Kringle Pharma

HGF (KP-100IT) protects neurons and promotes the extension of axons, it can be developed as a potential treatment for spinal cord injury. It is currently in Phase III for spinal cord injury. It is being developed by Kringle Pharma.

ES135: Eusol Biotech

ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. With its effect to promote neurite outgrowth, ES135 can be applied to the medical use of repairing neuron function. The sequence of ES135 has been patented in Taiwan, EU, China and the United States. A multi-center, double blind, randomized, placebo control study as the pivotal Phase 3 clinical trial for spinal cord injury is on-going.

Elezanumab: AbbVie

Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor thus potentially promoting neuroregeneration. It is currently in phase 2 stage of development.

Sovateltide: Pharmazz

Sovateltide is an endothelin B (ETB) receptor agonist. Activation of ETB receptors with PMZ-1620 produces neurovascular repair and remodeling or neuroregeneration. It is currently in Phase 2 for acute spinal cord injury.

FAB117-HC: Histocell

FAB117-HC is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2. The HC016 platform is a treatment of acute spinal cord injury in the initial stage of the lesion, based on mesenchymal stem cells derived from adipose tissue (ASC), and improved with Histocell's proprietary technology. Currently in phase 1/2 of development stage for spinal cord injuries.

NEU-2000: AmKor Pharma

NMDA antagonism and antioxidant action of Nelonemdaz (NEU-2000) would prevent the damages of brain and spinal cord cells induced by Traumatic Brain Injury (TBI) & Traumatic Spinal Cord Injury (TSI). It is currently in Phase I for spinal cord injury. Nelonemdaz is designed as the first multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+-permeable glutamate receptor, and free radicals, two major routes of neuronal death in stroke and traumatic brain/spinal cord injury.

Spinal cord injury: Therapeutic Assessment

This segment of the report provides insights about the different Spinal cord injury drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Spinal cord injury

There are approx. 35+ key companies which are developing the therapies for Spinal cord injury. The companies which have their Spinal cord injury drug candidates in the most advanced stage, i.e. phase III include, Kringle Pharma.


This report covers around 35+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Spinal cord injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intracerebral
  • Intramedullary injection
  • Intra-arterial
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Stem cell therapy
  • Growth factor
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spinal cord injury: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal cord injury therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal cord injury drugs.

Spinal cord injury Report Insights

  • Spinal cord injury Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Spinal cord injury Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Players

  • Pfizer
  • Eusol Biotech
  • Acorda
  • Pharmicell
  • StemCyte
  • Pharmazz
  • Neurofix
  • Mitsubishi
  • AbbVie
  • BioAxone
  • Novartis
  • Syntax
  • Histocell
  • Lineage Cell
  • ReNetX Bio
  • Nordic Life Sciences
  • Neuralstem
  • Mapreg
  • Amkor
  • AlaMab
  • Kancera
  • Neurofix Pharma
  • Scholar Rock
  • SanBio Co, Ltd.
  • Neurimmune
  • Novoron Biosciences
  • BioAxone BioSciences

Key Products

  • KP-100IT
  • ES135
  • Fampridine
  • Cellgram-spine
  • MC001
  • PMZ-1620
  • NFX88
  • MT-3921
  • Elezanumab
  • BA-210
  • ATI 355
  • Astrostem
  • FAB 117-HC
  • AST-OPC1
  • AXER-204
  • Spinalon
  • NSI-566
  • MAP4343
  • NEU-2000
  • CX 1739
  • KAND 567
  • NFX-81
  • Apitegromab
  • SB623
  • NG004
  • NOVO-118
  • NVG-291

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mgjzs


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900